




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 2





FIG. 3






FIG. 5A




FIG. 5B





FIG. 6

Ros9a Scaffold 19

MMGVKVLFALICIAVAEADLAKTTQPISVDSYEGQEVNITCSHNNIATNDYIT
WYQQFPSQGRFIIQGYKTKVTNEVASLFIPADRKSSLTSLPRVSLSDTAVYYC
LVGDMDAQGTALIFGKGTTLSSVDYIQNPDPVYQLRDSKSSDKFVCLFTDF
DSQIQVSQSKDSVYITDKCVLDMRSMDFKNSAVAWSQKSDFTCANAFQN
SIIPEDTFFPSPESCGSGHHHHHHHHRRIRSGSGVKQTLNFDLLKLAGDV
ESNPGMMGVKVLFALICIAVAEAAIQMTQSPSSLSASVGDRVTITCRASQDIR
NYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGTDYTLTISSLQPEDF
ATYYCQQGNTLPWTFGQGTKEIKGGGGSGGGSGGGSGGGSGGGSEV
QLVESGGGLVQPGGSLRLSCAASGYSTGYTMNWVRQAPGKGLEWVALINP
YKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGD
SDWYFDVWGQGTIVTVSSGGGGSAGVTQSPHLIKTRGQQVTLRCSPKSGH
DTVSWYQQALGQGPQFIFQYEEEEERQGNFPPDRFSGHQFPNYSSELNVNAL
LLGDSALYLCASSLGEGRVDGYTFGSGTRLTVVEDLKNVFPPEVAVFEPSKAE
ISRTQKATIVCLATGFYPPHVELSWWVNGKEVHDGVCTDPQPLKEQPALQDS
RYALSSRLRVSATFWQDPRNHFRCQVFYGLSENDEWTDRAKPVITQIVSAE
AWGRADCGGGGGLNDIFEAQKIEWHEGGGGGGGSLPETGG

(SEQ ID NO: 641)

FIG. 7A



Ros9a Scaffold 19

TCR name	Ros9a	pHLA antigen	GADGVGKSA (KRAS G12D 9mer) on HLA-C*08:02
CD3 binder	scFv Table 6A	K _D for pHLA	16 nM
Scaffold	19	Target cell line	A375 transduced with HLA-C*08:02 and KRAS G12CDRV minigene





FIG. 7B

Ros9a Scaffold 20b

MMGVKLFALICIAVAEAAIQMTQSPSSLSASVGDRVTTITCRASQDIR
NYLWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGGTDYTLTISSL
QPEDFATYYCQQGNTLPWTFGQGTKVEIKGGGGSGGGGGGGGG
GGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQ
APGKLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSL
RAEDTAVYYCARSGYYGDSDDWYFDVWGQGTLVTVSSGGGSAGVT
QSPTHLIKTRGQVTLRCSPKSGHDTVSWYQQALGQGPQFIFQYEE
EERQGNFPDRFSGHQFPNYSSELNVNALLLGDALYLCASSIGEGR
VDGYTFSGGTRLTVVGS
DYEFKSWTVEDLQKRLLALDPMMEQEIEE
IRQKYQCKRQPIILDAIEAKGGSGHHHHHHHHHRIRRSGSGATNFSLL
KQAGDVEENPGPMGVKVLFALICIAVAEADLAKTTQPISVDSYEGQ
EVNITCSHNNIATNDYITWYQQFPSPQPRFIIQGYKTKVTNEVASLFIP
ADRKSSLTSLPRVSLSDTAVYYCLVGDMDQAGTALIFGKGTTLISVCPD
GSDYEFKSWTVEDLQKRLLALDPMMEQEIEEIRQKYQCKRQPIILDAI
EAKGGSASWHPQFEK

(SEQ ID NO: 643)

FIG. 8A



Ros9a Scaffold 20b	
TCR name	Ros9a
Scaffold	20b
anti-CD3 binder	scFv Table 6A
pHLA antigen	GADGVGKSA (KRAS G12D 9mer) on HLA-C*08:02
K _D for pHLA	16 nM
Target cell line	A375 transduced with HLA-C*08:02 and KRAS G12CDRV minigene




FIG. 8B

Ros9a Scaffold 21


Chain A:

MMGVKLVFALICIAVAEADLAKTTQPI SVDSYEGQEVNITCSHNNIATNDYITWYQQFP
SQGPRFI IQGYKTKVTNEVASLFI PADRKSSSTLSLPRVSLSDTAVYYCLVGDMDQAGT
ALIFGKGTTL SVSSDYIQNPDPAVYQLRDSKSSDKFVCLFTDFDSQIQVSQSKDSDVYI
TDKCVLDMRSMDFKSN SAVAWSQKSDFTCANAFQNSII PEDTFFPSPSSCGGGGS
GGGGGGGSDKTHTCPPCPAPELLGGPSVFLFPKPKDTLMISRTPEVTCVVVDV
SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
KVSNAKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAV
EWESNGQPENNNYKTTTPPVLDSGSEFFLYSKLTVDKSRWQQGNVFCSSVMHEALHN
HYTQKSLSLSPGKGGGGGGGSLPETGGHHHHHHHHH (SEQ ID NO: 645)

Chain B:

MMGVKLVFALICIAVAEAAIQMTQSPSSLSASVGDRTVITCRASQDIRNYLNWYQQKPG
KAPKLLIYYTSRLESGVPSRFSGGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFG
QGTKVEIKGGGGSGGGSGGGSGGGSGGGSEVQLVESGGGLVQPGGSLRLSC
AASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTA
YIQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSSGGGGSDAGVTQS
PTHLIKTRGQQTLCRSPKSGHDTVSWYQQALGQGPQFIFQYEEEEERQGNFPDRF
SGHQFPNYSSELNVNALLGDSALYLCASSLGEGRVDGYTFGSGTRLTVVVEDLKNVFP
PEVAVFEPSKAEISRTQKATLVCLATGFYPPHVELSWWVNGKEVHDGVCCTDPQLKEQ
PALQDSRYALSSRLRVSATFWQDPRNHFRCQVQFYGLSENDEWTQDRAKPVTTQIVSA
EAWGRADCGGGSGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPKPKDTLE
ASRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL
HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLSC
AVKGFYPSDIAVEWESNGQPENNNYKTTTPPVLDSGSEFFLYSKLTVDKSRWQQGNVFS
CSVMHEALHNAYTQKSLSLSPGKGGGGGGLNDIIEFAQKIEWHE (SEQ ID NO: 646)

FIG. 9A



SUBSTITUTE SHEET (RULE 26)

Ros9a Scaffold 21

TCR name	Ros9a
Scaffold	21
anti-CD3 binder	scFv (Table 6A)
pHLA antigen	GADGVGKSA (KRAS G12D 9mer) on HLA-C*08:02
K _D for pHLA	16 nM
Target cell line	A375 transduced with HLA-C*08:02 and KRAS G12CDRV minigene




FIG. 9B

Ros9a Scaffold 19

MMGVKLVFALICIAVAEADLAKTTQPI SVDSYEGQEVNITCSH
NNIATNDYITWYQQFPSQGPRI IQGYKTKVTNEVASLFIPAD
RKSSTLSLPRVSLSDTAVYYCLVGDMDQAGTALIFGKGTLS
VSSDYIQNPDPVYQLRDSKSSDKFVCLFTDFDSQIQVSQSK
DSDVYITDKCVLDMRSMDFKNSAVAWSQKSDFTCANAFQ
NSIIPEDTFFPSPESSCSGSHHHHHHHHRRRSGSGVKQ
TLNFDLLKLAGDVESNPGPMGVKLVFALICIAVAEAAIQMTQ
SPSSLSASVGDRVITICRASQDIRNYLNWYQQKPKAPKLLI
YYTSRLESGVPSRFSGSGTDYTLTISSLQPEDFATYYCQQ
GNTLPWTFGQGTKEIKGGGGSGGGSGGGSGGGSG
GGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWV
RQAPGKLEWVALINPKGVSTYNQKFKDRFTISVDKSKNTA
YLQMNSLRAEDTAVYYCARSGYYGSDSDWYFDVWGQGLVT
VSSGGGGSAGVTQSPTHLIKTRGQQTLCSPKSGHDTV
WYQALGQGPQFI FQYEEEEERQRGNFPDRFSGHQFPNYS
SELNVNALLLGDSALYLCASSLGQTNYGTYFGSGTRLTVVED
LKNVFPPEVAVFEPKAEISRTQKATLVCLATGFYPPHVELS
WVNGKEVHDGVCTDPQLKEQPALQDSRYALSSRLRVSA
TFWQDPRNHFRCQVQFYGLSENDEWTQDRAKPVTVIVSAE
AWGRADCGGGGSLNDIFEAAQKIEWHEGGGGGGGGSLP
ETGG (SEQ ID NO: 647)




FIG. 10A

Ros9d Scaffold 19

TCR name	Ros9d
Scaffold	19
anti-CD3 binder	scFv
pHLA antigen	GADGVGKSA (KRAS G12D 9mer) on HLA-C*08:02
K _D for pHLA	125 nM
Target cell line	A375 transduced with HLA-C*08:02 and KRAS G12CDRV minigene




FIG. 10B

Ros9d Scaffold 21

TCR name	Ros9d
Scaffold	21
anti-CD3 binder	scFv
pHLA antigen	GADGVGKSA (KRAS G12D 9mer) on HLA-C*08:02
K _D for pHLA	125 nM
Target cell line	A375 transduced with HLA-C*08:02 and KRAS G12CDRV minigene




FIG. 11B

MMGVKLVFALICIAVAEAQKEVEQNSGPLSVPEGAIASLNCT
YSDRGSSFFWYRQYSGKSPELIMFIYSNGDKEDGRFETAQ
LNKASQYVSLIIRDSQPSDSATYLCAAAMDSSYKLIFFSGT
RLLRPDYIQNPDPVYQLRDSKSSDKFVCLFTDFDSQIQV
SQSKSDVYITDKCVLDMRSMDFKNSAVAWSQKSDFTCA
NAFQNSIIPEDTFFPSPSSCGSGHHHHHHHHRRRSGS
GVKQTLNFDLLKLAGDVESNPGPMGVKLVFALICIAVAEAA
IQMTQSPSSLASVGDRTITCRASQDIRNYLNWYQQKPG
KAPKLLIYYTSRLESGVPSRFSGSGTDYTLTISSLQPEDF
ATYQCQGNLTLPWTFGQGTKEIKGGGGSGGGSGGGG
SGGGSGGGSEVLVESGGGLVQPGGSLRLSCAASGYSF
TGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRF
TISVDKSKNTAYLQMNSLRAEDTAVYCARSGYYGSDDWY
FDVWGQGLVTVSSGGGSAGITQSPRYKITETGRQVTLM
CHQTSWHSYMFWRQDLGHGLRLIYSAADITDKGEVPD
GYVSRSKTENFPLTLESATRSQTSVYFCASSDPGTEAFFG
QGTRLTVVEDLKNVFPPEVAVFEPSKAEISRTQKATLVCLAT
GFYPHVELSWVNGKEVHDGVCTDPQPLKEQPALQDSR
YALSSRLRVSATFWQDPRNHFRQCQVFYGLSENDEWTQD
RAKPVQTIVSAEAWGRADCGGGGGLNDIFEAQKIEWHEG
GGSGGGGSLPETGG* (SEQ ID NO: 651)




FIG. 12A

Ros10 Scaffold 19

TCR name	Ros10
Scaffold	19
anti-CD3 binder	scFv
pHLA antigen	GADGVGKSAL (KRAS G12D 10mer) on HLA-C*08:02
K _D for pHLA	6.5 μM
Target cell line	A375 transduced with HLA-C*08:02 and KRAS G12CDRV minigene




FIG. 12B






FIG. 13








FIG. 16




FIG. 17




FIG. 18A

TRAV TRBV IgHC1 IgLC1 BAP 10XHis	TRAV TRBV IgHC1 IgLC1 BAP 10XHis	TRAV TRBV IgHC1 IgLC1 BAP 10XHis	TRAV TRBV IgHC1 IgLC1 BAP 10XHis
TRAV TRBV IgHC1 IgLC1 BAP 10XHis	TRAV TRBV IgHC1 IgLC1 BAP 10XHis	TRAV TRBV IgHC1 IgLC1 BAP 10XHis	TRAV TRBV IgHC1 IgLC1 BAP 10XHis

FIG. 18B




FIG. 19




FIG. 20




FIG. 21






FIG. 22

Ros9a Scaffold 22




TCR name	Ros9a
Scaffold	22
Anti-CD3 binder	scFv from New Scaffold group - TR66 VLVH
pHLA	GADGVGKSA (KRAS G12D 9mer) HLA-C*08 02
K _D for pHLA	16 nM
Target cell line	A375 transduced with HLA-C*08 02 and KRASG12CDRV minigene




MMGVKVLFAICIAVAEADLAKTTQPISVDSYEGQEVNITCSHNNIATNDYIT
WYQQFPSQGPRFIIQGYKTKVTNEVASLFIPADRKSSTLSLPRVSLSDTAVY
YCLVGDMQAGTALIFGKGTTLSVSSDYIQNPDPAVYQLRDSKSSDKFVCL
FTDFDSQIQVSQSKDSDVYITDKCVLDMRSMDFKSNSAVAWSQKSDFTC
NAFQNSIIPEDTFFPSPSSCGSGHHHHHHHHHRIIRSGSGVKQTLNFD
LLKLAGDVESNPGPMGVKVLFAICIAVAEAQIVLTQSPAISASPGKVT
MTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVYPYRFSGSGSGTS
YSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKGGGSGGGGSGG
GGSGGGGSGGGGSQVQLQQSGAELARPGASVKMSCKTSGYTFTRYTM
HWVKQRPQGQLEWIGYINPSRGYTNYNQKFKDKATLTDDKSSSTAYMQLS
SLTSEDSAVYYCARYYDDHYSLDYWGQGTTLTVSSGGGGSAGVTQSPH
LIKTRGQQVTLRCSPKSGHDTVSWYQQALGQGPQFIFQYEEEEERQRGN
FPDRFSGHQFPNYSSELNVNALLGDSALYLCASSLGEGRVDGYTFGSGT
RLTVVEDLKNVFPPEVAVFEPKAEISRTQKATLVCLATGFYPPHVELSWW
VNGKEVHDGVCTDPQPLKEQPALQDSRYALSSRLRVSATFWQDPRNHFR
CQVQFYGLSENDEWTQDRAKPVTTQIVSAEAWGRADCGGGGSGGLNDIFEA
QKIEWHEGGGGSGGGGSLPETGG*

FIG. 24

Ros9a Scaffold 22




TCR name	Ros9a
Scaffold	22
Anti-CD3 binder	scFv from New Scaffold group - 210112 VHVL
pHLA	GADGVGKSA (KRAS G12D 9mer) HLA-C*08 02
K _D for pHLA	16 nM
Target cell line	A375 transduced with HLA-C*08 02 and KRASG12CDRV minigene




MMGVKVLFAICIAVAEADLAKTTQPIISVDSYEQEVNITCSHNNIATNDYITWYQQFSPSQGPRFIIQ
GYKTKVTNEVASLFIPADRKSSTLSLPRVSLSDTAVYYCLVGDMQAGTALIFGKGTTLSSSDYIQ
NPDPAVYQLRDSKSSDKFVCLFTDFDSQIQVSQSKDSVYITDKCVLDMRSMDFKSNSAVAWSQ
KSDFTCANAFQNSIIPEDTFFPSPESSCGSGHHHHHHHHHRIRRS GSGVKQTLNFDLLKLAGDV
ESNPGPMMGVKVLFAICIAVAEAQVQLVQSGGGLVQPGGPLRLSCTASGFSFSNNYYMCWVRQ
APGKGLEWVSCIYTNIGSTWYASWAKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARGIYSD
SSDFIGNLWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSAIQMTQSPSSLSASVGDRTITCQ
ASQTIYNYLAWYQQKPGKVPPELLIYKASTLASGVPSRFMTGFGTDFTLTIDSLQPEDAATYYCQQ
YNTIINVDRFTFGGGTKVEIKGGGGSAGVTQSPTHLIKTRGQQVTLRCSPKSGHDTVSWYQQALG
QGPQFIFQYEEEEERQQRGNFPDRFSGHQFPNYSSELNVNALLGDSALYLCASSLGEGRVDGYT
FGSGTRLTVVEDLKNVFPPEVAVFEPKAEISRTQKATLVCLATGFYPPHVELSWWVNGKEVHDG
VCTDPQPLKEQPALQDSRYALSSRLRVSATFWQDPRNHFRQVQFYGLSENDEWTQDRAKPVT
QIVSAEAWGRADCGGGGSLNDIFEAQKIEWHEGGGGSGGGGSLPETGG*

FIG. 25

Ros9a Scaffold 22



TCR name	Ros9a
Scaffold	22
Anti-CD3 binder	scFv from New Scaffold group - 210112 VLVH
pHLA	GADGVGKSA (KRAS G12D 9mer) HLA-C*08 02
K _D for pHLA	16 nM
Target cell line	A375 transduced with HLA-C*08 02 and KRASG12CDRV minigene



MMGVKVLFAICIAVAEADLAKTTQPISVDSYEGQEVNITCSHNNIATNDYITWYQQFSPSQGPRFIIQ
GYKTKVTNEVASLFIPADRKSSLSLPRVSLSDTAVYYCLVGDMQAGTALIFGKGTLSVSSDYIQ
NPDPAVYQLRDSKSSDKFVCLFTDFDSQIQVSQSKDSVYITDKCVLDMRSMDFKSNSAVAWSQ
KSDFTCANAFQNSIIPEDTFFPSPESSCGSGHHHHHHHHHRIRRS GSGVKQTLNFDLLKLAGDV
ESNPGPMMGVKVLFAICIAVAEAAIQMTQSPSSLSASVGDRVTITCQASQTIYNLAWYQQKPGK
VPELLIYKASTLASGVPSRFMTGFGTDFTLTIDSLQPEDAATYYCQQYNTIINVDRTFGGGTKVEI
KGGGGSGGGSGGGSGGGSGGGSGGGSGVQLVQSGGGLVQPGGPLRLSCTASGFSFSNNYYM
CWVRQAPGKGLEWVSCIYTNNIGSTWYASWAKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCA
RGIYSDSSDFIGNLWGQGTLLTVSSGGGSAGVTQSPTHLIKTRGQQVTLRCSPKSGHDTVSWY
QQALGQGPQFIFQYYEEEEERQRGNFPDRFSGHQFPNYSSELNVNALLGDSALYLCASSLGEGR
VDGYTFGSGTRLTVVEDLKNVFPPEVAVFEP SKAEISRTQKATLVCLATGFYPPHVELSWVNGK
EVHDGVCTDPQPLKEQPALQDSRYALSSRLRV SATFWQDPRNHFR CQVQFYGLSENDEWTQDR
AKPVTQIVSAEAWGRADCGGGGSLNDIFEAQKIEWHEGGGGSGGGGSLPETGG*

FIG. 26





FIG. 27



MMGVKVLFALICIAVAEADLAKTTQPISVDSYEGQEVNITCSHNNIATNDYITWYQQFPSQGPRFIIQGY
KTKVTNEVASLFIPADRKSSSTLSLPRVSLSDTAVYYCLVGDMDQAGTALIFGKGTTLSVSSDYIQNPDP
AVYQLRDSKSSDKFVCLFTDFDSQIQVSQSKDSVDYITDKCVLDMRSMDFKSNSAVAWSQKSDFTC
ANAFQNSIIPEDTFFPSPESSCGSGHHHHHHHHHRIRRSRSGSGVKQTLNFDLLKLAGDVESNPGPM
MGVKVLFALICIAVAEAQVQLVQSGGGLVQPGGPLRLSCTASGFSFSNNYYMCWVRQAPGKGLEWV
SCIYTNNIGSTWYASWAKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCARGIYSDSSDFIGNLWGQ
GTLVTVSSGGGGSGGGSGGGSGGGGSAIQMTQSPSSLSASVGDRTTITCQASQTIYNYLAWYQ
QKPGKVPPELLIYKASTLASGVPSRFMTGFGTDFTLTIDSLQPEDAATYYCQQYNTIINVDRTFGGGT
KVEIKGGGGSAGVTQSPTHLIKTRGQQVTLRCSPKSGHDTVSWYQQALGQGPQFIFQYEEEEERQR
GNFPDRFSGHQFPNYSSELNVNALLLGDSALYLCASSLGQTNYGYTFGSGTRLTVVEDLKNVFPPEV
AVFEPKAEISRTQKATLVCLATGFYPPHVELSWWVNGKEVHDGVCTDPQLKEQPALQDSRYALSS
RLRVSATFWQDPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGGGGSLNDIFE
AQKIEWHEGGGGSGGGGSLPETGG*

FIG. 28




FIG. 29




FIG. 30




FIG. 31

Tumor cell line: HPAC
E:T ratio of 2:1 for conditions
with T cells
Annexin V apoptotic signal quantified




FIG. 32





FIG. 34






FIG. 35B





FIG. 36






FIG. 38




FIG. 39A




FIG. 39B





FIG. 40






FIG. 41 (Cont.)